No Data
No Data
HC Wainwright & Co. Reiterates Buy on Regenxbio, Maintains $39 Price Target
H.C. Wainwright Maintains Regenxbio(RGNX.US) With Buy Rating, Maintains Target Price $39
H.C. Wainwright analyst Yi Chen maintains $Regenxbio(RGNX.US)$ with a buy rating, and maintains the target price at $39.According to TipRanks data, the analyst has a success rate of 27.9% and a
Positive Clinical Trials and Regulatory Milestones Bolster Buy Rating for RegenXBio
RegenxBio Touts Positive Data for Rare Disease Drug RGX-121
Express News | Regenxbio Inc - 80% of Patients Who Received Pivotal Dose Discontinued Intravenous Enzyme Replacement Therapy or Remained Treatment-Naïve
Express News | Regenxbio Inc - Submission of a Rolling Bla Using Accelerated Approval Pathway on Track for Q3 2024